Analysts have increased their price target for Granules India from ₹604.29 to ₹632.14, citing improved revenue growth forecasts. These forecasts are considered significant enough to offset a slight reduction in projected profit margins.
What's in the News
- A board meeting is scheduled for November 13, 2025, to consider and approve unaudited financial results for the second quarter and half-year ended September 30, 2025. The board will also discuss the potential acquisition of a 160 percent equity stake in M/s. optus 1039, GmBH, Frankfurt, Germany (Board Meeting).
- The company has received an Establishment Inspection Report from the U.S. FDA for the API Unit-I facility in Bonthapally, Hyderabad, following an inspection in June 2025 that was classified as Voluntary Action Indicated. One observation from the inspection was addressed by the company within the stipulated time (Regulatory Authority – Compliance).
- The API Unit-I facility is recognized as one of the largest single-site Paracetamol API manufacturing plants globally by volume. It also houses Metformin and Guaifenesin API production (Regulatory Authority – Compliance).
Valuation Changes
- Consensus Analyst Price Target has increased from ₹604.29 to ₹632.14, reflecting an upgrade in fair value estimates.
- Discount Rate remains unchanged at 12.76 percent.
- Revenue Growth is now forecast at 14.45 percent, up from the previous estimate of 13.88 percent.
- Net Profit Margin has declined slightly to 13.29 percent, down from 13.58 percent previously.
- Future P/E has risen to 22.83x from 21.63x, indicating higher valuation expectations.
Have other thoughts on Granules India?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.